Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | Using the Kras <sup>LSL-G12D</sup> lung cancer model, we show that mutant Kras drives a lipogenic gene-expression program. | 29906244 | 2018 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Collectively, these data demonstrate that in the LSL-K-ras<sup>G12D</sup> murine lung cancer model, inflammatory macrophage-Th17 cell axis is critical to tumorigenesis and that IL-10 blocks this process primarily via a direct effect on the former. | 30257887 | 2018 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | To extend the in vitro study, we employed both xenograft model and LSL- K-ras G12D lung cancer model to examine the role of miR-188 in tumorigenesis. | 29528232 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | We translated our findings to two murine models of lung cancer, including orthotopic human xenograft and Kras<sup>LSL/G12D</sup> mouse models of lung cancer. | 28345958 | 2017 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | In comparison, MALT1 deficiency does not affect tumor progression in a mouse model (LSL-K-ras(G12D); CCSP-Cre; Malt1(-/-)) in which lung cancer is induced by expressing a K-ras mutant. | 25982276 | 2016 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Co-administration of BI-2536 and fasudil either in the LSL-KRAS(G12D) mouse model or in a patient tumour explant mouse model of KRAS-mutant lung cancer suppresses tumour growth and significantly prolongs mouse survival, suggesting a strong synergy in vivo and a potential avenue for therapeutic treatment of KRAS-mutant cancers. | 27193833 | 2016 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | The therapeutic potential of microRNAs for preventing and treating lung cancer using the Kras(LSL-G12D/+);p53(LSL-R172H/+)mouse model suggests that miR-34 may be useful in sensitizing tumors to other conventional therapeutics. | 23487440 | 2013 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Using an inducible LSL-KRAS(G12D) model of lung cancer in vivo, we show a transient upregulation of Notch pathway activity in early tumor precursor lesions. | 21994468 | 2011 |